Hepatitis C–associated late-onset schizophrenia: a nationwide, population-based cohort study
Authors:
Open Access
- 21 December 2021
- journal article
- research article
- Published by Canadian Science Publishing in Journal of Psychiatry and Neuroscience
- Vol. 46 (6) , E583-E591
Abstract
Background: Whether infection with the hepatitis C virus (HCV) causes schizophrenia — and whether the associated risk reverses after anti-HCV therapy — is unknown; we aimed to investigate these topics. Methods: We conducted a nationwide, population-based cohort study using the Taiwan National Health Insurance Research Database (TNHIRD). A diagnosis of schizophrenia was based on criteria from the International Classification of Diseases, 9th revision (295.xx). Results: From 2003 to 2012, from a total population of 19 298 735, we enrolled 3 propensity-score-matched cohorts (1:2:2): HCV-treated (8931 HCV-infected patients who had received interferon-based therapy for ≥ 6 months); HCV-untreated (17 862); and HCV-uninfected (17 862) from the TNHIRD. Of the total sample (44 655), 82.81% (36 980) were 40 years of age or older. Of the 3 cohorts, the HCV-untreated group had the highest 9-year cumulative incidence of schizophrenia (0.870%, 95% confidence interval [CI] 0.556%–1.311%; p < 0.001); the HCV-treated (0.251%, 95% CI 0.091%–0.599%) and HCV-uninfected (0.118%, 95% CI 0.062%–0.213%) cohorts showed similar cumulative incidence of schizophrenia (p = 0.33). Multivariate Cox analyses showed that HCV positivity (hazard ratio [HR] 3.469, 95% CI 2.168–5.551) was independently associated with the development of schizophrenia. The HCV-untreated cohort also had the highest cumulative incidence of overall mortality (20.799%, 95% CI 18.739%–22.936%; p < 0.001); the HCV-treated (12.518%, 95% CI 8.707%–17.052%) and HCV uninfected (6.707%, 95% CI 5.533%–8.026%) cohorts showed similar cumulative incidence of mortality (p = 0.12). Limitations: We were unable to determine the precise mechanism of the increased risk of schizophrenia in patients with HCV infection. Conclusion: In a population-based cohort (most aged ≥ 40 years), HCV positivity was a potential risk factor for the development of schizophrenia; the HCV-associated risk of schizophrenia might be reversed by interferon-based antiviral therapy.Keywords
This publication has 42 references indexed in Scilit:
- Occult and Overt HBV Co-Infections Independently Predict Postoperative Prognosis in HCV-Associated Hepatocellular CarcinomaPLOS ONE, 2013
- An integrative functional genomics approach for discovering biomarkers in schizophreniaBriefings in Functional Genomics, 2011
- Human endogenous retrovirus type W (HERV-W) in schizophrenia: A new avenue of research at the gene–environment interfaceThe World Journal of Biological Psychiatry, 2011
- Chlamydophila pneumoniaeInfection and Its Role in Neurological DisordersInterdisciplinary Perspectives on Infectious Diseases, 2010
- The influence of antiviral therapy on psychiatric symptoms among patients with hepatitis C and schizophreniaAntiviral Therapy, 2010
- Parasitic brain infection, endocannabinoids, and schizophreniaMedical Hypotheses, 2009
- Congenital Viral Infections of the Brain: Lessons Learned from Lymphocytic Choriomeningitis Virus in the Neonatal RatPLOS Pathogens, 2007
- Rate and predictors of treatment prescription for hepatitis CGut, 2006
- Search for Hepatitis C Virus Negative-Strand RNA Sequences and Analysis of Viral Sequences in the Central Nervous System: Evidence of ReplicationJournal of Virology, 2002
- Adapting a clinical comorbidity index for use with ICD-9-CM administrative databasesJournal of Clinical Epidemiology, 1992